Twist Bioscience Corporation $TWST Stock Holdings Lifted by Rafferty Asset Management LLC

Rafferty Asset Management LLC lifted its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 51.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 114,268 shares of the company’s stock after acquiring an additional 38,608 shares during the quarter. Rafferty Asset Management LLC owned 0.19% of Twist Bioscience worth $3,216,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of TWST. Campbell & CO Investment Adviser LLC increased its position in shares of Twist Bioscience by 227.6% in the third quarter. Campbell & CO Investment Adviser LLC now owns 47,200 shares of the company’s stock worth $1,328,000 after acquiring an additional 32,792 shares in the last quarter. Thrivent Financial for Lutherans boosted its stake in Twist Bioscience by 14.5% in the 3rd quarter. Thrivent Financial for Lutherans now owns 1,463,085 shares of the company’s stock worth $41,171,000 after purchasing an additional 184,726 shares during the period. Baillie Gifford & Co. grew its position in Twist Bioscience by 62.8% during the 3rd quarter. Baillie Gifford & Co. now owns 1,262,739 shares of the company’s stock worth $35,533,000 after purchasing an additional 487,052 shares in the last quarter. New York State Common Retirement Fund grew its position in Twist Bioscience by 14.0% during the 3rd quarter. New York State Common Retirement Fund now owns 584,694 shares of the company’s stock worth $16,453,000 after purchasing an additional 71,777 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Twist Bioscience by 13.2% during the 2nd quarter. American Century Companies Inc. now owns 864,384 shares of the company’s stock valued at $31,801,000 after purchasing an additional 100,978 shares during the period.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on TWST shares. Robert W. Baird set a $50.00 price target on Twist Bioscience in a report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, December 29th. Barclays increased their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 3rd. Evercore boosted their price objective on shares of Twist Bioscience from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Tuesday, February 3rd. Finally, TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Seven research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $45.88.

Twist Bioscience Stock Up 1.7%

Shares of Twist Bioscience stock opened at $46.65 on Wednesday. The firm has a market cap of $2.86 billion, a price-to-earnings ratio of -36.45 and a beta of 2.23. The stock has a 50-day simple moving average of $42.73 and a 200-day simple moving average of $34.21. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $57.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.02). The business had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The firm’s revenue was up 16.9% compared to the same quarter last year. On average, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, Director Jan Johannessen sold 2,200 shares of the firm’s stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $47.91, for a total transaction of $105,402.00. Following the transaction, the director directly owned 17,754 shares in the company, valued at $850,594.14. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Emily M. Leproust sold 5,001 shares of the business’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $46.58, for a total value of $232,946.58. Following the completion of the sale, the chief executive officer directly owned 869,312 shares of the company’s stock, valued at $40,492,552.96. This represents a 0.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 36,609 shares of company stock worth $1,665,151 in the last ninety days. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.